Business
Medexus Schedules First Fiscal Quarter 2024 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 2, 2023) - Medexus Pharmaceutica...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus Schedules First Fiscal Quarter 2024 Conference CallToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 2, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 10, 2023 to discuss Medexus's results for its first fiscal quarter ended June 30, 2023. Medexus expects to file its financial statements and MD&A after markets close on August 9, 2023.To participate in the call, please dial the following numbers:888-506-0062 (toll-free) for Canadian and U.S. callers+1 973-528-0011 for international callersAccess code: 550553A live webcast of the call will be available on the Investors section of Medexus's corporate website or at the following link:https://www.webcaster4.com/Webcast/Page/2010/48802A replay of the call will be available approximately one hour following the end of the call through Thursday, August 17, 2023. To access the replay, please dial the following numbers -877-481-4010 for Canadian and U.S. callers+1 919-882-2331 for international callersConference ID: 48802A replay of the webcast will be available on the Investors section of Medexus's corporate website until Saturday, August 10, 2024.About MedexusMedexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca. ContactsKen d'Entremont | CEO, Medexus PharmaceuticalsTel: 905-676-0003 | Email: [email protected] Konrad | CFO, Medexus PharmaceuticalsTel: 312-548-3139 | Email: [email protected] Rutherford | Adelaide CapitalTel: 480-625-5772 | Email: [email protected] statementsCertain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words \"anticipates\", \"believes\", \"expects\", \"will\", \"plans\", \"potential\", and similar words, phrases, or expressions are often intended to identify forward-looking...